XRME:XETRA:XETRA-Xtrackers MSCI USA ESG Screened UCITS ETF 2C EUR Hedged (EUR)

ETF | Others |

Last Closing

USD 9.869

Change

+0.00 (+0.01)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.48 (+0.95%)

USD 420.85B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.16 (+0.96%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.22 (+0.82%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.27 (+0.96%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.29 (+1.18%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.35 (+0.78%)

USD 102.32B
8R80:XETRA Amundi Index Solutions - Amund..

+1.10 (+0.77%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.53 (+1.07%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.08 (+0.08%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.16 (+0.20%)

USD 80.38B

ETFs Containing XRME:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.15% 87% B+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.15% 87% B+ 84% B
Trailing 12 Months  
Capital Gain 24.73% 89% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.73% 89% A- 86% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.38% 74% C 71% C-
Dividend Return 10.38% 73% C 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.69% 53% F 62% D
Risk Adjusted Return 88.84% 92% A 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike